[111In-DTPA-D-Phe]-OCTREOTIDE SCINTIGRAPHY IN METASTATIC HORMONE-REFRACTORY PROSTATIC ADENOCARCINOMA WITH HIGH CHROMOGRANIN A

被引：0
|
作者：
Villa, G.
Borzone, C. [1 ]
Sambuceti, G.
Carmignani, G. [1 ]
机构：
[1] Urol Clin, Genoa, Italy
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
280
引用
收藏
页码：1537 / 1538
页数：2
相关论文
共 34 条
  • [1] METASTATIC HORMONE-REFRACTORY PROSTATIC ADENOCARCINOMA EXPRESSES SOMATOSTATIN RECEPTORS AND IS VISUALIZED IN-VIVO BY [IN-111]-LABELED DTPA-D-[PHE(1)]-OCTREOTIDE SCINTIGRAPHY
    NILSSON, S
    REUBI, JC
    KALKNER, KM
    LAISSUE, JA
    HORISBERGER, U
    OLERUD, C
    WESTLIN, JE
    CANCER RESEARCH, 1995, 55 (23) : S5805 - S5810
  • [2] [111In-DTPA-D-Phe1]-Octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment:: A pilot study
    Kälkner, KM
    Nilsson, S
    Westlin, JE
    ANTICANCER RESEARCH, 1998, 18 (1B) : 513 - 516
  • [3] Treatment of patients with neuroendocrine tumors with [111In-DTPA-D-Phe]-octreotide -: The Uppsala experience
    Janson, ET
    Garske, U
    Westlin, JE
    Welin, S
    Örlefors, H
    Granberg, D
    Skogseid, B
    Eriksson, B
    Öberg, K
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 294 - 295
  • [4] LOCALIZATION OF METASTATIC GASTROENTEROPANCREATIC TUMORS BY SOMATOSTATIN RECEPTOR SCINTIGRAPHY WITH [IN-111-DTPA-D-PHE(1)]-OCTREOTIDE
    HAMMOND, PJ
    ARKA, A
    PETERS, AM
    BLOOM, SR
    GILBEY, SG
    QUARTERLY JOURNAL OF MEDICINE, 1994, 87 (02): : 83 - 88
  • [5] SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN METASTATIC HORMONE-REFRACTORY PROSTATIC-CARCINOMA
    KALKNER, KM
    GINMAN, C
    WESTLIN, JE
    LETOCHA, H
    NILSSON, S
    ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, 1995, 8 (01): : 11 - 21
  • [6] Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
    Kalkner, KM
    Acosta, S
    Thorsson, O
    Frederiksen, H
    Nilsson, A
    Gustavsson, B
    Elingsbo, M
    Stridsberg, M
    Abrahamsson, PA
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (01) : 92 - 98
  • [7] Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
    K M Kalkner
    S Acosta
    O Thorsson
    H Frederiksen
    A Nilsson
    B Gustavsson
    M Elingsbo
    M Stridsberg
    P-A Abrahamsson
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 92 - 98
  • [8] (111Indium-DTPA-D-Phe) octreotide scintigraphy in the diagnostic assessment of palpable breast lumps
    Parker, SJ
    Barker, CPG
    McLeod, MA
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S74 - S74
  • [9] Functional imaging of langerhans cell histiocytosis by 111In-DTPA-D-Phe1-octreotide scintigraphy
    Lastoria, S
    Montella, L
    Catalano, L
    Rotoli, B
    Muto, P
    Palmieri, G
    CANCER, 2002, 94 (03) : 633 - 640
  • [10] Radiation doses deriving from patients undergoing 111In-DTPA-d-Phe-1-octreotide scintigraphy
    Amir Kurtaran
    Josef Pfreitfellner
    Peter Schaffarich
    Peter Smith-Jones
    Bruno Niederle
    Markus Raderer
    Irene Virgolini
    Helmar Bergmann
    Ernst Havlik
    European Journal of Nuclear Medicine, 1997, 24 : 1298 - 1300
1234